Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2826749 | 0.79 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL3112463 | 0.76 | HSD11B1 (0.50) | HSD11B1HSD11B2 | |
| SCHEMBL158815 | 0.74 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL975067 | 0.72 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL975066 | 0.72 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL12093270 | 0.72 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| Hydrochloric Acid SCHEMBL27500985 | 0.72 | HSD11B1 (0.52) | HSD11B1 | |
| SCHEMBL3661870 | 0.72 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL975068 | 0.72 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL176523 | 0.71 | ALDH1A1 (0.52) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| EP-4583976-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-07-16 | — | — | EP | disclosed |
| EP-4583977-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025104123-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-22 | — | — | WO | disclosed |
| WO-2024052513-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052512-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | WO | disclosed |
| US-20230301171-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230301171-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| CN-116462713-A | Organometallic compound, light-emitting device including the same, and electronic device | 三星显示有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230225190-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2006023821-A2 | LIGANDS FOR ALDOKETOREDUCTASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | disclosed |
| US-6875762-B2 | Tetracyclic azepinoindole compounds | PFIZER (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | PHARMACIA AND UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | disclosed |
| US-6407092-B1 | 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-06-18 | — | — | US | disclosed |
| US-5750409-A | MARKERS FOR HAPTEN-ANTIBODY-PROTEIN CONJUGATES | BOEHRINGER MANNHEIM GMBH (DE) | 1998-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301171-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | CRY1, GPX1, NFE2L2 | HSD11B1 939/4885HSD11B2 1389/4885 |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | HSD11B1 1564/4885HSD11B2 1357/4885 |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK1, JAK3 | HSD11B1 2192/4885HSD11B2 2090/4885 |
| US-20040138202-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HSD11B1 1144/4885HSD11B2 1140/4885 |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HSD11B1 1144/4885HSD11B2 1140/4885 |
| US-20230225190-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | LIG1, CRY1, LAGE3 | HSD11B1 829/4885HSD11B2 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.